中文摘要：

乳腺癌是女性最常见的恶性肿瘤之一,中国女性乳腺癌发病率逐年上升。人表皮生长因子受体2（human epidermal growth factor receptor-2,HER-2）在近三分之一的乳腺癌患者中呈现基因扩增或受体蛋白高表达。HER-2阳性的乳腺癌患者预后差,术后复发风险高、生存期短。曲妥珠单抗是人表皮生长因子受体-2的特异性抑制剂[1],在HER-2阳性乳腺癌患者的治疗中得到了广泛的应用,并且曲妥珠单抗分子靶向治疗相比于传统的化疗,具有特异性较强,毒副反应相对较小等优点。它改变了HER-2阳性乳腺癌患者的自然疾病进程,延长了患者的生存时间。本文将从四个方面对曲妥珠单抗在HER-2阳性乳腺癌患者治疗中的研究、应用及进展进行综述。

英文摘要：

Breast cancer is one of the most common malignancies happened in female patients.The incidence of breast cancer in Chinese females has increased in recently years.Human epidermal growth factor receptor-2（HER-2） exhibits gene amplification or high expression of receptor protein in about one third of breast cancer patients.HER-2 positive breast cancer patients has poor prognosis,high risk of recurrence and short survival.Trastuzumab is a specific inhibitor of human epidermal growth factor receptor-2[1],which has been widely used in the treatment of HER-2-positive breast cancer patients,and trastuzumab molecular targeting therapy compared with the traditional chemotherapy,with the advantages of high specificity and low toxicity.It changes the natural disease progression of patients with HER-2-positive breast cancer and prolongs the patient＇s survival time.This article will review the researches on the four aspects,which including the development and the application of trastuzumab in the treatment of HER-2 positive breast cancer.